Deutsche Bank Ag\ Lexicon Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 315,659 shares of LXRX stock, worth $246,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares

315,659

Previous 66,043 377.96%

Holding current value

$246,214

Previous $103,000 126.21%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.65 - $2.08 $162,250 - $519,201	249,616 Added 377.96%	315,659 $233,000
Q3 2024 Nov 13, 2024	BUY	$1.51 - $2.39 $51,571 - $81,625	34,153 Added 107.1%	66,043 $103,000
Q2 2024 Aug 14, 2024	SELL	$1.54 - $2.28 $10,544 - $15,611	-6,847 Reduced 17.68%	31,890 $53,000
Q1 2024 May 15, 2024	SELL	$1.3 - $3.58 $2,017 - $5,556	-1,552 Reduced 3.85%	38,737 $92,000
Q2 2023 Aug 14, 2023	SELL	$2.15 - $3.49 $26,522 - $43,052	-12,336 Reduced 23.44%	40,289 $92,000
Q1 2023 May 15, 2023	BUY	$1.99 - $2.68 $31,798 - $42,823	15,979 Added 43.6%	52,625 $127,000
Q4 2022 Feb 13, 2023	BUY	$1.8 - $2.56 $1,000 - $1,423	556 Added 1.54%	36,646 $69,000
Q3 2022 Nov 14, 2022	BUY	$1.94 - $3.43 $5,816 - $10,283	2,998 Added 9.06%	36,090 $87,000
Q2 2022 Aug 11, 2022	SELL	$1.31 - $2.69 $6,291 - $12,920	-4,803 Reduced 12.67%	33,092 $61,000
Q1 2022 May 13, 2022	SELL	$1.95 - $3.89 $8,806 - $17,567	-4,516 Reduced 10.65%	37,895 $80,000
Q4 2021 Feb 11, 2022	BUY	$3.81 - $6.16 $8,221 - $13,293	2,158 Added 5.36%	42,411 $167,000
Q3 2021 Nov 04, 2021	SELL	$3.38 - $5.35 $425,974 - $674,249	-126,028 Reduced 75.79%	40,253 $194,000
Q2 2021 Aug 11, 2021	BUY	$4.12 - $5.87 $322,525 - $459,521	78,283 Added 88.96%	166,281 $764,000
Q1 2021 May 13, 2021	SELL	$3.45 - $9.09 $224,864 - $592,468	-65,178 Reduced 42.55%	87,998 $516,000
Q4 2020 Feb 16, 2021	SELL	$1.05 - $3.67 $489,461 - $1.71 Million	-466,154 Reduced 75.27%	153,176 $524,000
Q3 2020 Nov 12, 2020	BUY	$1.44 - $2.1 $862,729 - $1.26 Million	599,118 Added 2964.17%	619,330 $892,000
Q2 2020 Aug 13, 2020	BUY	$1.75 - $2.3 $10,638 - $13,981	6,079 Added 43.01%	20,212 $40,000
Q1 2020 May 14, 2020	SELL	$1.8 - $4.28 $157,181 - $373,742	-87,323 Reduced 86.07%	14,133 $27,000
Q4 2019 Feb 14, 2020	SELL	$3.16 - $5.15 $81,202 - $132,339	-25,697 Reduced 20.21%	101,456 $420,000
Q3 2019 Nov 14, 2019	SELL	$1.2 - $6.66 $182,450 - $1.01 Million	-152,042 Reduced 54.46%	127,153 $381,000
Q2 2019 Aug 14, 2019	BUY	$5.35 - $7.11 $101,799 - $135,289	19,028 Added 7.31%	279,195 $1.75 Million
Q1 2019 May 15, 2019	SELL	$4.36 - $7.94 $154,570 - $281,488	-35,452 Reduced 11.99%	260,167 $1.44 Million
Q4 2018 Feb 14, 2019	SELL	$6.15 - $10.51 $67,176 - $114,800	-10,923 Reduced 3.56%	295,619 $1.96 Million
Q3 2018 Dec 21, 2021	BUY	$10.32 - $13.06 $1.08 Million - $1.37 Million	105,117 Added 52.19%	306,542 $3.27 Million
Q3 2018 Nov 14, 2018	SELL	$10.32 - $13.06 $1.34 Million - $1.7 Million	-130,263 Reduced 39.27%	201,425 $2.15 Million
Q2 2018 Apr 21, 2020	BUY	$7.8 - $13.69 $157,622 - $276,647	20,208 Added 6.49%	331,688 $3.98 Million
Q2 2018 Aug 14, 2018	SELL	$7.8 - $13.69 $902,366 - $1.58 Million	-115,688 Reduced 27.08%	311,480 $3.74 Million
Q1 2018 Oct 18, 2019	BUY	$7.86 - $11.39 $942,476 - $1.37 Million	119,908 Added 39.02%	427,168 $3.66 Million
Q1 2018 May 15, 2018	SELL	$7.86 - $11.39 $1.89 Million - $2.74 Million	-240,859 Reduced 43.94%	307,260 $2.63 Million
Q4 2017 Feb 14, 2018	BUY	$8.77 - $12.28 $1.9 Million - $2.67 Million	217,214 Added 65.64%	548,119 $5.41 Million
Q3 2017 Nov 14, 2017	BUY	$12.17 - $16.3 $4.03 Million - $5.39 Million	330,905	330,905 $4.06 Million

Others Institutions Holding LXRX

# of Institutions

132

Shares Held

238M

Call Options Held

37.3K

Put Options Held

144K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $147M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account